Soriano V - Search Results

1

Hepatitis C therapy with HCV NS5B polymerase inhibitors.

Soriano V, Vispo E, de Mendoza C, Labarga P, Fernandez-Montero JV, Poveda E, Treviño A, Barreiro P. Soriano V, et al. Expert Opin Pharmacother. 2013 Jun;14(9):1161-70. doi: 10.1517/14656566.2013.795543. Epub 2013 Apr 27. Expert Opin Pharmacother. 2013. PMID: 23621117 Review.

2

Genetic mechanisms of resistance to protease inhibitors and entry inhibitors.

Soriano V, de Mendoza C. Soriano V, et al. HIV Clin Trials. 2002 May-Jun;3(3):249-57. doi: 10.1310/hct.2002.3.3.009. HIV Clin Trials. 2002. PMID: 12032884 Review.

3

Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection.

Sheldon J, Barreiro P, Soriano V. Sheldon J, et al. Among authors: soriano v. Expert Opin Investig Drugs. 2007 Aug;16(8):1171-81. doi: 10.1517/13543784.16.8.1171. Expert Opin Investig Drugs. 2007. PMID: 17685867 Review.

4

Update on the treatment of chronic hepatitis C in HIV-infected patients.

Soriano V, Barreiro P, Martin-Carbonero L, Vispo E, Garcia-Samaniego J, Labarga P, Gonzalez-Lahoz J. Soriano V, et al. AIDS Rev. 2007 Apr-Jun;9(2):99-113. AIDS Rev. 2007. PMID: 17694677 Review.

5

Emerging drugs for hepatitis C.

Soriano V, Madejon A, Vispo E, Labarga P, Garcia-Samaniego J, Martin-Carbonero L, Sheldon J, Bottecchia M, Tuma P, Barreiro P. Soriano V, et al. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19. doi: 10.1517/14728214.13.1.1. Expert Opin Emerg Drugs. 2008. PMID: 18321145 Review.

6

Hepatitis B in HIV patients: what is the current treatment and what are the challenges?

Soriano V, Tuma P, Vispo E, Labarga P, Fernández JV, Medrano J, Barreiro P. Soriano V, et al. J HIV Ther. 2009 Mar;14(1):13-8. J HIV Ther. 2009. PMID: 19731560

7

Viral hepatitis and HIV co-infection.

Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Soriano V, et al. Antiviral Res. 2010 Jan;85(1):303-15. doi: 10.1016/j.antiviral.2009.10.021. Epub 2009 Nov 1. Antiviral Res. 2010. PMID: 19887087 Review.

8

Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients.

Treviño A, de Mendoza C, Parra P, Rodríguez C, Madejón A, Plaza Z, del Romero J, Poveda E, Soriano V. Treviño A, et al. Among authors: soriano v. Antivir Ther. 2011;16(3):413-6. doi: 10.3851/IMP1760. Antivir Ther. 2011. PMID: 21555824

9

Directly acting antivirals against hepatitis C virus.

Soriano V, Vispo E, Poveda E, Labarga P, Martin-Carbonero L, Fernandez-Montero JV, Barreiro P. Soriano V, et al. J Antimicrob Chemother. 2011 Aug;66(8):1673-86. doi: 10.1093/jac/dkr215. Epub 2011 Jun 7. J Antimicrob Chemother. 2011. PMID: 21652618 Review.

10

Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients.

Plaza Z, Soriano V, Gonzalez Mdel M, Di Lello FA, Macias J, Labarga P, Pineda JA, Poveda E. Plaza Z, et al. Among authors: soriano v. J Antimicrob Chemother. 2011 Dec;66(12):2838-42. doi: 10.1093/jac/dkr385. Epub 2011 Sep 27. J Antimicrob Chemother. 2011. PMID: 21954459

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,490 results

Search Page

Filters